113 related articles for article (PubMed ID: 16118401)
21. Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats.
Hodde JP; Suckow MA; Wolter WR; Hiles MC
J Surg Res; 2004 Aug; 120(2):189-94. PubMed ID: 15234212
[TBL] [Abstract][Full Text] [Related]
22. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
Sava T; Basso U; Porcaro A; Cetto GL
Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
[TBL] [Abstract][Full Text] [Related]
23. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer.
Sato M; Johnson M; Zhang L; Gambhir SS; Carey M; Wu L
Clin Cancer Res; 2005 May; 11(10):3743-9. PubMed ID: 15897571
[TBL] [Abstract][Full Text] [Related]
24. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
Hamberg P; Verhagen PC; de Wit R
Eur J Cancer; 2008 Jun; 44(9):1193-7. PubMed ID: 18448326
[TBL] [Abstract][Full Text] [Related]
25. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
26. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
27. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.
Bubendorf L; Kolmer M; Kononen J; Koivisto P; Mousses S; Chen Y; Mahlamäki E; Schraml P; Moch H; Willi N; Elkahloun AG; Pretlow TG; Gasser TC; Mihatsch MJ; Sauter G; Kallioniemi OP
J Natl Cancer Inst; 1999 Oct; 91(20):1758-64. PubMed ID: 10528027
[TBL] [Abstract][Full Text] [Related]
28. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide.
Pollard M; Luckert PH; Sporn MB
Cancer Res; 1991 Jul; 51(13):3610-1. PubMed ID: 1829024
[TBL] [Abstract][Full Text] [Related]
29. Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives.
Autorino R; Di Lorenzo G; Damiano R; De Placido S; D'Armiento M
Urol Int; 2003; 70(1):1-14. PubMed ID: 12566808
[TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor expression in primary prostate cancers of Lobund-Wistar rats and in tumor-derived cell lines.
Bentel JM; Pickering MA; Pollard M; Clements JA; Tilley WD
In Vitro Cell Dev Biol Anim; 1999; 35(10):655-62. PubMed ID: 10614877
[TBL] [Abstract][Full Text] [Related]
32. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
33. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.
Pollard M; Luckert PH
J Natl Cancer Inst; 1986 Aug; 77(2):583-7. PubMed ID: 3461217
[TBL] [Abstract][Full Text] [Related]
34. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
Inoue T; Segawa T; Kamba T; Yoshimura K; Nakamura E; Nishiyama H; Ito N; Kamoto T; Habuchi T; Ogawa O
Urology; 2009 May; 73(5):1104-9. PubMed ID: 19394511
[TBL] [Abstract][Full Text] [Related]
36. Prevention of induced prostate-related cancer by soy protein isolate/isoflavone-supplemented diet in Lobund-Wistar rats.
Pollard M; Wolter W; Sun L
In Vivo; 2000; 14(3):389-92. PubMed ID: 10904871
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer.
Pollard HB; Levine MA; Eidelman O; Pollard M
In Vivo; 2010; 24(3):249-55. PubMed ID: 20554995
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
39. State-of-the-art treatment of metastatic hormone-refractory prostate cancer.
Goodin S; Rao KV; DiPaola RS
Oncologist; 2002; 7(4):360-70. PubMed ID: 12185298
[TBL] [Abstract][Full Text] [Related]
40. Expression of osteocalcin in prostate cancer before and after hormonal therapy.
Ou YC; Chen JT; Yang CR; Ko JL; Hsieh YS; Kao C
Anticancer Res; 2003; 23(5A):3807-11. PubMed ID: 14666681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
